Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on June 6, 2023, and filed on June 7, 2023, by bioAffinity Technologies, Inc. (Nasdaq: BIAF). The filing details the results of the Company's 2023 Annual Meeting of Stockholders, including the election of directors and the approval of corporate governance amendments.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial performance metrics.
Material Changes and Corporate Actions
- Equity Incentive Plan Amendment: Stockholders approved an amendment to the 2014 Equity Incentive Plan, increasing the number of shares reserved for issuance from 1,142,857 to 2,000,000 shares. The plan became effective on June 6, 2023.
- Authorized Share Increase: Stockholders approved an amendment to the Certificate of Incorporation, increasing the number of authorized Common Stock shares from 14,285,715 to 25,000,000. This amendment became effective on June 7, 2023, upon filing with the Delaware Secretary of State.
- Director Elections: Seven directors were elected to serve until the 2024 Annual Meeting: Maria Zannes, Steven Girgenti, Robert Anderson, Stuart Diamond, Peter Knight, Mohsin Meghji, and Gary Rubin.
- Auditor Ratification: Stockholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Voting Results and Management Commentary
At the Annual Meeting, 6,433,619 votes were represented, constituting 75.43% of the voting power and establishing a quorum. All four proposals were approved by the stockholders.
- Proposal 1 (Directors): All seven nominees received significant support, with "For" votes ranging from approximately 4.79 million to 4.81 million per nominee.
- Proposal 2 (Incentive Plan): Approved with 4,687,779 votes For, 129,731 Against, and 92,253 Abstentions.
- Proposal 3 (Share Increase): Approved with 4,748,470 votes For, 68,889 Against, and 92,404 Abstentions.
- Proposal 4 (Auditor): Ratified with 6,340,312 votes For, 4,857 Against, and 88,450 Abstentions.
The filing notes that the Company is an emerging growth company. No specific risks, contingencies, or unusual items were disclosed in this specific report beyond the standard corporate actions.
Investor Verification Checklist
- Verify the impact of the increased authorized share count (25,000,000 shares) on potential future dilution.
- Review the full text of the Amended and Restated 2014 Equity Incentive Plan (Exhibit 10.1) to understand the terms of the additional 857,143 shares reserved for awards.
- Confirm the composition of the Board of Directors following the election of the seven nominees.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.